National trends in cerebral bypass surgery in the United States, 2002-2014.

AHRQ = Agency for Healthcare Research and Quality COSS = Carotid Occlusion Surgery Study ECIC = extracranial-intracranial NIS = National (Nationwide) Inpatient Sample PED = Pipeline embolization device US = United States cerebral aneurysm cerebral bypass moyamoya disease national trends vascular occlusion

Journal

Neurosurgical focus
ISSN: 1092-0684
Titre abrégé: Neurosurg Focus
Pays: United States
ID NLM: 100896471

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 01 10 2018
accepted: 14 11 2018
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 24 4 2020
Statut: ppublish

Résumé

OBJECTIVECerebral bypass procedures are microsurgical techniques to augment or restore cerebral blood flow when treating a number of brain vascular diseases including moyamoya disease, occlusive vascular disease, and cerebral aneurysms. With advances in endovascular therapy and evolving evidence-based guidelines, it has been suggested that cerebral bypass procedures are in a state of decline. Here, the authors characterize the national trends in cerebral bypass surgery in the United States from 2002 to 2014.METHODSUsing the National (Nationwide) Inpatient Sample, the authors extracted for analysis the data on all adult patients who had undergone cerebral bypass as indicated by ICD-9-CM procedure code 34.28. Indications for bypass procedures, patient demographics, healthcare costs, and regional variations are described. Results were stratified by indication for cerebral bypass including moyamoya disease, occlusive vascular disease, and cerebral aneurysms. Predictors of inpatient complications and death were evaluated using multivariable logistic regression analysis.RESULTSFrom 2002 to 2014, there was an increase in the annual number of cerebral bypass surgeries performed in the United States. This increase reflected a growth in the number of cerebral bypass procedures performed for adult moyamoya disease, whereas cases performed for occlusive vascular disease or cerebral aneurysms declined. Inpatient complication rates for cerebral bypass performed for moyamoya disease, vascular occlusive disease, and cerebral aneurysm were 13.2%, 25.1%, and 56.3%, respectively. Rates of iatrogenic stroke ranged from 3.8% to 20.4%, and mortality rates were 0.3%, 1.4%, and 7.8% for moyamoya disease, occlusive vascular disease, and cerebral aneurysms, respectively. Multivariate logistic regression confirmed that cerebral bypass for vascular occlusive disease or cerebral aneurysm is a statistically significant predictor of inpatient complications and death. Mean healthcare costs of cerebral bypass remained unchanged from 2002 to 20014 and varied with treatment indication: moyamoya disease $38,406 ± $483, vascular occlusive disease $46,618 ± $774, and aneurysm $111,753 ± $2381.CONCLUSIONSThe number of cerebral bypass surgeries performed for adult revascularization has increased in the United States from 2002 to 2014. Rising rates of surgical bypass reflect a greater proportion of surgeries performed for moyamoya disease, whereas bypasses performed for vascular occlusive disease and aneurysms are decreasing. Despite evolving indications, cerebral bypass remains an important surgical tool in the modern endovascular era and may be increasing in use. Stagnant complication rates highlight the need for continued interest in advancing available bypass techniques or technologies to improve patient outcomes.

Identifiants

pubmed: 30717065
doi: 10.3171/2018.11.FOCUS18530
pii: 2018.11.FOCUS18530
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E4

Auteurs

Ethan A Winkler (EA)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

John K Yue (JK)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Hansen Deng (H)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Kunal P Raygor (KP)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Ryan R L Phelps (RRL)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Caleb Rutledge (C)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Alex Y Lu (AY)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Roberto Rodriguez Rubio (R)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Jan-Karl Burkhardt (JK)

2Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.

Adib A Abla (AA)

1Department of Neurological Surgery, University of California, San Francisco, California; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH